CKD-516 HCl
WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#:205833
CAS#:1240321-53-2 ( HCl salt)
Description:CKD-516 is tubulin inhibitor for solid cancer, which was initiated phase 1 trial in Korea in 2010. CKD-516 selectively disrupted tubulin component of the endothelial cytoskeleton. Serial DCE-MRI showed a significant decrease in K-trans and IAUGC parameters from baseline at 4 h (39.9 % in K-trans; -45.0 % in IAUGC) and at 24 h (-32.2 % in K-trans; -36.5 % in IAUGC), and a significant recovery at 48 h (22.9 % in K-trans; 34.8 % in IAUGC) following administration of CKD-516 at a 0.7-mg/kg dose. When the tumors were stratified according to the initial K-trans value of 0.1, tumors with a high K-trans > 0.1 which was indicative of having well-developed pre-existing vessels, showed greater reduction in K-trans and IAUGC values.
Price and Availability
CKD-516 HClis not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.
Chemical Structure
Theoretical Analysis
MedKoo Cat#: 205833Name: CKD-516 HClCAS#: 1240321-53-2 ( HCl salt)Chemical Formula: C26H29ClN6O5SExact Mass: Molecular Weight: 573.06Elemental Analysis: C, 54.49; H, 5.10; Cl, 6.19; N, 14.67; O, 13.96; S, 5.60
Synonym:CKD516; CKD-516; CKD 516; CKD 516 HCl.
IUPAC/Chemical Name:(S)-N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide hydrochloride
InChi Key:FIAUXCMEQTWLQZ-FTBISJDPSA-N
InChi Code:InChI=1S/C26H28N6O5S.ClH/c1-14(2)22(27)25(34)31-26-30-18(11-38-26)15-6-7-17(19(8-15)32-13-28-12-29-32)23(33)16-9-20(35-3)24(37-5)21(10-16)36-4;/h6-14,22H,27H2,1-5H3,(H,30,31,34);1H/t22-;/m0./s1
SMILES Code:CC(C)[C@H](N)C(NC1=NC(C2=CC=C(C(C3=CC(OC)=C(OC)C(OC)=C3)=O)C(N4N=CN=C4)=C2)=CS1)=O.[H]Cl
Technical Data
Additional Information
Related: 1240321-53-2 (CKD-516 HCl salt) 1188371-47-2 (CKD-516 free base).
References
1: Kim KW, Lee JM, Jeon YS, Lee IJ, Choi Y, Park J,Kiefer B, Kim C, Han JK, Choi BI. Vascular disrupting effect of CKD-516:preclinical study using DCE-MRI. Invest New Drugs. 2013Oct;31(5):1097-106. doi: 10.1007/s10637-012-9915-6. Epub 2013 Jan 9.Erratum in: Invest New Drugs. 2013 Oct;31(5):1397. PubMed PMID:23299389.
我国旅美科学家陈清奇博士创立的MedKoo美帝药库医药公司目前正在建立全球第一个小分子抗癌药库。 MedKoo是一家以研发、生产和销售小分子抗癌化合物为主的医药科技公司。 业务范围 为全球所有从事抗癌药物研究和开发的制药公司,高校,研究院所,政府相关机构提供与抗癌药物分子相关的产品、试剂和技术服务。 技术核心 以药物化学合成技术为核心,密切结合全球抗癌新药研发领域中的新技术、新理论、新趋势和新的发展方向,不断推出抗癌化合物新品种。 建造目标 MedKoo美帝药库的目标是:建成全球最大的小分子抗癌药库 ,品种最多最全、质量最好最可靠。美帝药库的宗旨是:客户第一;质量第一;信誉第一;创新第一。